Therapy of Hypertension in End-Stage Renal Disease

Roy, Louise; Leenen, Frans H. H.

doi:10.1007/978-1-4615-3902-5_16

Cited by 4 publications

(1 citation statement)

References 107 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Besides, the ideal frequency of DW evaluation is variously appreciated by various authors. Some recommend an evaluation when volume [15] or hypertension [16] is not controlled; others advise a monthly [17] or even less frequent evaluation. In Tassin, DW is re‐evaluated after each and every session by the physician or the person in charge of the patient.…”

Section: How Is Ecv Assessed?mentioning

confidence: 99%

Clinical Determination of Dry Body Weight

Charra

Gadrey

Hurot

et al. 2001

Hemodialysis International

View full text Add to dashboard Cite

While nephrologists wait for the ideal, non invasive, inexpensive, precise, and reproducible tool to evaluate extracellular volume (ECV), they need to exert their clinical acumen in the quest of that holy grail, dry weight (DW). Estimation of DW using a clinical approach based on blood pressure (BP) and ECV is feasible and reliable as shown by successful experiences in various dialysis modes over more than three decades. But a need still exists to resolve difficulties associated with accurate assessment of BP (methods and circumstances of measurement, and the confounding effects of antihypertensive drugs) and ECV (evaluation of weight changes unrelated to ECV, lack of specificity and sensitivity of clinical symptoms, lag time, confusion in terminology). An essential point in clinical assessment of DW is that a normal BP is at the same time the target and the crucial index of DW achievement. For this reason, a trialand-error "probe" process has to be used at intervals to make sure that the dry weight target point is correctly estimated. The various "non clinical" methods proposed for dry weight assessment increase the complexity and the cost of hemodialysis. They are, in the present state of things, more clinical research than practice tools. They do not replace clinical judgment.

show abstract

Section: How Is Ecv Assessed?mentioning

confidence: 99%

Clinical Determination of Dry Body Weight

Charra

Gadrey

Hurot

et al. 2001

Hemodialysis International

View full text Add to dashboard Cite

show abstract

Renal Parenchymal Hypertension: current concepts of pathogenesis and management

Preston¹,

Singer²,

Epstein³

1996

Archives of Internal Medicine

View full text Add to dashboard Cite

Renal parenchymal disease is a common but often unrecognized cause of hypertension. Chronic renal disease and systemic hypertension may coexist in two distinct settings. First, essential hypertension is an important cause of chronic renal disease. Second, renal parenchymal disease is a well-established cause of secondary hypertension. Renal parenchymal disease is the most common cause of secondary hypertension, accounting for 2.5% to 5.0% of all cases of systemic hypertension. Secondary hypertension may also accelerate the decline in renal function if inadequately controlled. Therefore, hypertension is both a cause and a consequence of renal disease, and it may be difficult to distinguish them clinically.

show abstract